Real world Effectiveness of Sotrovimab in Preventing COVID-19–related Hospitalisation or Death in Patients Infected with Omicron BA.2

DOI record: { "DOI": "10.1016/j.jiph.2023.11.029", "ISSN": [ "1876-0341" ], "URL": "http://dx.doi.org/10.1016/j.jiph.2023.11.029", "alternative-id": [ "S1876034123004355" ], "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Real world Effectiveness of Sotrovimab in Preventing COVID-19–related Hospitalisation or Death in Patients Infected with Omicron BA.2" }, { "label": "Journal Title", "name": "journaltitle", "value": "Journal of Infection and Public Health" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.jiph.2023.11.029" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2023 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences." } ], "author": [ { "ORCID": "http://orcid.org/0009-0001-2414-8857", "affiliation": [], "authenticated-orcid": false, "family": "Behzad", "given": "Alwaleed", "sequence": "first" }, { "affiliation": [], "family": "Mohamed", "given": "Aamal", "sequence": "additional" }, { "affiliation": [], "family": "Ali", "given": "Ahmed", "sequence": "additional" }, { "affiliation": [], "family": "Niinuma", "given": "Sara", "sequence": "additional" }, { "affiliation": [], "family": "Butler", "given": "Alexandra E", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-1523-0429", "affiliation": [], "authenticated-orcid": false, "family": "Alqahtani", "given": "Manaf", "sequence": "additional" } ], "container-title": "Journal of Infection and Public Health", "container-title-short": "Journal of Infection and Public Health", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.fr", "clinicalkey.jp", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2023, 12, 4 ] ], "date-time": "2023-12-04T17:08:01Z", "timestamp": 1701709681000 }, "deposited": { "date-parts": [ [ 2023, 12, 4 ] ], "date-time": "2023-12-04T17:08:34Z", "timestamp": 1701709714000 }, "indexed": { "date-parts": [ [ 2023, 12, 5 ] ], "date-time": "2023-12-05T00:24:14Z", "timestamp": 1701735854453 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2023, 12 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 12, 1 ] ], "date-time": "2023-12-01T00:00:00Z", "timestamp": 1701388800000 } }, { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 11, 30 ] ], "date-time": "2023-11-30T00:00:00Z", "timestamp": 1701302400000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S1876034123004355?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S1876034123004355?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "prefix": "10.1016", "published": { "date-parts": [ [ 2023, 12 ] ] }, "published-print": { "date-parts": [ [ 2023, 12 ] ] }, "publisher": "Elsevier BV", "reference": [ { "key": "10.1016/j.jiph.2023.11.029_bib1", "unstructured": "Tracking sars-COV-2 variants [Internet]. World Health Organization. World Health Organization; [cited 21 Nov2022]. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants/" }, { "article-title": "SARS-COV-2 variant evasion of monoclonal antibodies based on in vitro studies", "author": "Cox", "journal-title": "Nature Reviews Microbiology", "key": "10.1016/j.jiph.2023.11.029_bib2", "year": "2022" }, { "DOI": "10.1056/NEJMoa2107934", "article-title": "Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab", "author": "Gupta", "doi-asserted-by": "crossref", "first-page": "1941", "issue": "21", "journal-title": "N Engl J Med", "key": "10.1016/j.jiph.2023.11.029_bib3", "volume": "385", "year": "2021" }, { "DOI": "10.1002/rmv.2381", "article-title": "Evolution of the sars‐cov‐2 omicron variants BA.1 to Ba.5: Implications for immune escape and transmission", "author": "Shrestha", "doi-asserted-by": "crossref", "issue": "5", "journal-title": "Reviews in Medical Virology", "key": "10.1016/j.jiph.2023.11.029_bib4", "volume": "32", "year": "2022" }, { "article-title": "Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2", "author": "Kawaoka", "journal-title": "Res Sq", "key": "10.1016/j.jiph.2023.11.029_bib5", "year": "2022" }, { "DOI": "10.1038/s41591-022-01792-5", "article-title": "Serum neutralization of SARS-COV-2 omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies", "author": "Bruel", "doi-asserted-by": "crossref", "first-page": "1297", "issue": "6", "journal-title": "Nature Medicine", "key": "10.1016/j.jiph.2023.11.029_bib6", "volume": "28", "year": "2022" }, { "DOI": "10.1038/s41586-022-04594-4", "article-title": "Antibody evasion properties of SARS-CoV-2 Omicron sublineages", "author": "Iketani", "doi-asserted-by": "crossref", "journal-title": "Nature.", "key": "10.1016/j.jiph.2023.11.029_bib7", "year": "2022" }, { "article-title": "In vitro activity of therapeutic antibodies against SARS-COV-2 omicron Ba.1, Ba.2 and BA.5", "author": "Touret", "issue": "1", "journal-title": "Scientific Reports", "key": "10.1016/j.jiph.2023.11.029_bib8", "volume": "12", "year": "2022" }, { "DOI": "10.1016/j.antiviral.2022.105372", "article-title": "Different efficacies of neutralizing antibodies and antiviral drugs on SARS-COV-2 omicron subvariants, Ba.1 and BA.2", "author": "Ohashi", "doi-asserted-by": "crossref", "journal-title": "Antiviral Research", "key": "10.1016/j.jiph.2023.11.029_bib9", "volume": "205", "year": "2022" }, { "DOI": "10.3390/v14061334", "article-title": "Resistance of SARS-COV-2 omicron ba.1 and BA.2 variants to vaccine-elicited Sera and therapeutic monoclonal antibodies", "author": "Zhou", "doi-asserted-by": "crossref", "first-page": "1334", "issue": "6", "journal-title": "Viruses", "key": "10.1016/j.jiph.2023.11.029_bib10", "volume": "14", "year": "2022" }, { "DOI": "10.1016/j.ebiom.2022.104158", "article-title": "Limited neutralisation of the SARS-COV-2 omicron subvariants BA.1 and BA.2 by convalescent and Vaccine Serum and monoclonal antibodies", "author": "Wilhelm", "doi-asserted-by": "crossref", "journal-title": "eBioMedicine", "key": "10.1016/j.jiph.2023.11.029_bib11", "volume": "82", "year": "2022" }, { "DOI": "10.1016/j.chom.2022.04.017", "article-title": "SARS-COV-2 omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies", "author": "Arora", "doi-asserted-by": "crossref", "issue": "8", "journal-title": "Cell Host & Microbe", "key": "10.1016/j.jiph.2023.11.029_bib12", "volume": "30", "year": "2022" }, { "DOI": "10.3390/v14071374", "article-title": "Efficacy of licensed monoclonal antibodies and antiviral agents against the SARS-COV-2 omicron sublineages BA.1 and BA.2", "author": "Fiaschi", "doi-asserted-by": "crossref", "first-page": "1374", "issue": "7", "journal-title": "Viruses.", "key": "10.1016/j.jiph.2023.11.029_bib13", "volume": "14", "year": "2022" }, { "key": "10.1016/j.jiph.2023.11.029_bib14", "unstructured": "U.S. Food and Drug Administration. Fact Sheet For Healthcare Providers Emergency Use Authorization (EUA) Of Sotrovimab [Internet].2022 [Updated March 2022, Cited 20 Oct 2022]. Available from: https://www.fda.gov/media/149534/download" }, { "DOI": "10.1016/j.ijid.2022.09.023", "article-title": "Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-COV-2 in Qatar", "author": "Zaqout", "doi-asserted-by": "crossref", "first-page": "96", "journal-title": "International Journal of Infectious Diseases", "key": "10.1016/j.jiph.2023.11.029_bib15", "volume": "124", "year": "2022" }, { "DOI": "10.1093/ofid/ofac411", "article-title": "Real-world clinical outcomes of Bebtelovimab and SOTROVIMAB treatment of high-risk persons with coronavirus disease 2019 during the omicron epoch", "author": "Razonable", "doi-asserted-by": "crossref", "issue": "10", "journal-title": "Open Forum Infectious Diseases", "key": "10.1016/j.jiph.2023.11.029_bib16", "volume": "9", "year": "2022" }, { "key": "10.1016/j.jiph.2023.11.029_bib17", "unstructured": "F.D.A. Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19 [Internet]. U.S. Food and Drug Administration; 2021 [cited 2022 Nov 21]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19" }, { "DOI": "10.1016/j.jinf.2022.06.033", "article-title": "Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2", "author": "Martin-Blondel", "doi-asserted-by": "crossref", "first-page": "e104", "issue": "4", "journal-title": "J Infect", "key": "10.1016/j.jiph.2023.11.029_bib18", "volume": "85", "year": "2022" }, { "DOI": "10.1016/S1473-3099(21)00751-9", "article-title": "Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial", "author": "Self", "doi-asserted-by": "crossref", "first-page": "622", "issue": "5", "journal-title": "Lancet Infect Dis", "key": "10.1016/j.jiph.2023.11.029_bib19", "volume": "22", "year": "2022" }, { "key": "10.1016/j.jiph.2023.11.029_bib20", "unstructured": "Mazzotta V., Cozzi Lepri A., Colavita F., Rosati S., Lalle E., Cimaglia C., et al. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents. J Med Virol. 10.1002/jmv.28186" }, { "DOI": "10.1101/2022.03.21.22272672", "doi-asserted-by": "crossref", "key": "10.1016/j.jiph.2023.11.029_bib21", "unstructured": "Stadler E., Chai K.L., Schlub T.E., Cromer D., Polizzotto M.N., Kent S.J., et al. Determinants of passive antibody efficacy in SARS-CoV-2 infection. medRxiv. 2022 Aug 4;" }, { "key": "10.1016/j.jiph.2023.11.029_bib22", "unstructured": "Gliga S., Luebke N., Killer A., Gruell H., Walker A., Dilthey A.T., et al. Rapid selection of sotrovimab escape variants in SARS-CoV-2 Omicron infected immunocompromised patients. Clin Infect Dis. 10.1093/cid/ciac802" }, { "key": "10.1016/j.jiph.2023.11.029_bib23", "unstructured": "NHRA. Bahrain COVID-19 national protocols. [Internet]. National Health Regulatory authority Bahrain; 2020 [cited 2020 Jan 07]. Available from: https://www.nhra.bh/Media/Announcement/MediaHandler/GenericHandler/documents/Announcements/NHRA_News_MOH%20ALERT_Bahrain%20COVID-19%20National%20Protocols_20200701.pdf" } ], "reference-count": 23, "references-count": 23, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S1876034123004355" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases", "Public Health, Environmental and Occupational Health", "General Medicine" ], "subtitle": [], "title": "Real world Effectiveness of Sotrovimab in Preventing COVID-19–related Hospitalisation or Death in Patients Infected with Omicron BA.2", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy" }